Highest-materiality recent filing
enVVeno receives FDA IDE approval for pivotal study of non-surgical venous valve; $25M cash
FDA grants first-ever IDE for a U.S. pivotal study of a non-surgical replacement venous valve (enVVe System).
enVVeno Medical regains Nasdaq minimum bid price compliance; reports $28M cash at year-end
Received formal Nasdaq notice confirming compliance with minimum bid price rule; closing bid ≥ $1.00 for 10 consecutive business days Jan 20 - Feb 2, 2026, matter closed.
enVVeno Medical effects 1:35 reverse stock split, shares outstanding drop to ~655,606
Reverse split ratio 1:35 effective Jan 20, 2026; no fractional shares issued, rounded up.
enVVeno stockholders reject 2025 equity plan; authorize reverse stock split
Elected Jenusaitis (3.47M for, 1.80M withheld) and Berman (4.73M for, 0.54M withheld) as Class II directors.
enVVeno Medical lowers stockholder meeting quorum to 33-1/3% voting power
Board approved amendment to Section 1.5 of Amended and Restated Bylaws on November 17, 2025.
enVVeno loses FDA appeal for VenoValve PMA; shifts focus to enVVe device
Unfavorable FDA appeal upheld not-approvable letter for VenoValve (received Aug 19, 2025).
enVVeno Medical enters ATM offering agreement for up to $50M of common stock
Agreement with Ladenburg Thalmann allows sale of up to $50M of common stock from time to time.
enVVeno Medical receives Nasdaq bid-price deficiency notice; cure period to April 2026
Nasdaq notified enVVeno on Oct 7, 2025 that bid price closed below $1.00 for 30 consecutive business days.
enVVeno receives FDA not-approvable letter for VenoValve PMA
FDA issued not-approvable letter for VenoValve PMA, citing insufficient benefit-risk profile.
enVVeno Medical appoints Jennifer Bright as CFO, replacing Craig Glynn
Craig Glynn resigned as CFO effective May 19, 2025; will serve as consultant for transition.
enVVeno Medical replaces auditor Marcum with CBIZ CPAs after acquisition of Marcum's attest business
Marcum resigned as auditor effective April 17, 2025; CBIZ CPAs engaged with Audit Committee approval.
enVVeno Medical reports annual meeting results; elects two directors, approves say-on-pay frequency
Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for three-year terms.
enVVeno Medical closes $15M public offering of common stock and pre-funded warrants
Gross proceeds of ~$15M from sale of 4,206,106 common shares and 79,609 pre-funded warrants at $3.50/$3.4999.
72% of SAVVE trial patients achieved ≥3-point rVCSS improvement at a weighted average of 11 months post-surgery.
97% of VenoValve study patients showed clinical improvement at six months measured by revised Venous Clinical Severity Score (rVCSS).
enVVeno stockholders elect Robert C. Gray as Class III director, ratify Marcum LLP as auditor
Robert C. Gray elected as Class III director for three-year term (5.48M votes for, 0.89M withheld, 2.78M broker non-votes).
Preliminary device-related MAE rate 8% for fully enrolled 75-patient SAVVE trial; no deaths or pulmonary embolisms.
enVVeno raises $28M in PIPE financing with milestone-based warrants
Gross proceeds of $28M from sale of 3,844,704 shares, pre-funded warrants for 977,900 shares, and two tranches of warrants.
Robert A. Berman re-elected with 2,378,488 votes for, 697,978 withheld; 2,373,744 broker non-votes.
enVVeno files 8-K/A correcting shareholder vote tallies for annual meeting
Corrected vote counts show Dr. Francis Duhay received 3,420,358 votes for; Dr. Sanjay Shrivastava 3,342,772 votes for as Class I directors.
enVVeno expects 9 SAVVE trial sites active; shareholders approve director elections, plan amendments
Elected Dr. Francis Duhay and Dr. Sanjay Shrivastava as Class I directors for terms ending at 2024 annual meeting.
Hancock Jaffe Laboratories renamed enVVeno Medical; new tickers NVNO and NVNOW
Name change effective 12:01 a.m. Eastern on October 1, 2021.
Hancock Jaffe to rename enVVeno Medical, focus on venous disease; VenoValve trial to start
Name change to enVVeno Medical Corporation, tickers NVNO/NVNW effective Oct 1, 2021.
Hancock Jaffe raises $20M in registered direct offering with Perceptive Advisors
Gross proceeds of $20M from sale of 781,615 shares at $7.872/share and pre-funded warrants for 1,759,035 shares at $0.0001 exercise.
Hancock Jaffe enters $25M ATM equity offering with Ladenburg Thalmann
Up to $25M of common stock may be sold through Ladenburg Thalmann as agent.
On May 19, 2025, the Board of Directors (the “ Board ”) of enVVeno Medical Corporation (the “ Company ”) appointed Jennifer Bright as Chief Financial Officer of the Company.
On May 19, 2025, Craig Glynn resigned as Chief Financial Officer of the Company.
Max materiality 0.95 · Median 0.60 · Most common event other_material